Related topics:
Abbott Laboratories stories:
Study Questions Utility Of Merck Cholesterol Drugs
Nov 18th, 2009 - Wall Street Journal
(Adds analyst reaction beginning in eighth paragraph and updated stock price.) A new study by health insurer UnitedHealth Group Inc. (UNH) concludes Merck & Co.'s...
Niacin Bests Zetia in Cholesterol Study
Nov 17th, 2009 - Wall Street Journal
Bring out the niacin. That's the simplest message from a small but long-awaited study comparing Abbott Laboratories' niacin-based drug Niaspan against Merck Inc.'s cholesterol-lowering medicine Zetia.
Doctors gird for patient anxiety over Zetia data
Nov 16th, 2009 - Reuters
ORLANDO, Florida (Reuters) - The good news for Merck & Co's Zetia cholesterol fighter is that doctors do not seem unduly concerned about its latest setback in a clinical trial...
UPDATE 1-Merck up as Zetia trial less damaging than feared
Nov 16th, 2009 - Reuters
* Zetia trial results less damaging to Merck than expected * Merck shares rise 2.7 pct; Abbott up 1.3 pct * Trial results presented at AHA meeting in Orlando (Updates with details, additional analyst comment) BOSTON, Nov...
US Stocks Surge To Fresh 2009 Highs; DJIA Up 135
Nov 16th, 2009 - Wall Street Journal
NEW YORK (Dow Jones)--U.S. stocks surged Monday, with all three major indexes hitting new intraday highs for 2009, as a report of robust economic growth in Japan sparked a rally in energy and materials firms.



